New Development Targets Prevention of Severe Respiratory Syncytial Virus Infections The U.S. Food and Drug Administration (FDA) has granted approval for Pfizer's RSV vaccine, Abrysvo, aimed at preventing lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults aged 18 to 59 who are